New York, New York – (Newsfile Corp. – January 24, 2025) – WHY: The Rosen Law Firm, a Global Investor Rights Law Firm, reminds buyers of securities at Cassava Sciences, Inc. the important February 10, 2025 leads the Deadline of the complaint.

Whats up: If you purchase Cassava securities during class time you can be entitled to compensation that is free of charge from the pocket bills or costs by a contingency fee arrangement.

What to do next: To participate in Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq. Toll-free at 866-767-3653 or email [email protected] for information on the action in class. Class Action Case has been filed. If you want to serve a lead plaintiff, you need to move the court No more than February 10, 2025. The leading complement is a representative party that works for other members of the litigation classroom.

Why Rosen Law: We encourage investors to choose qualified advisors with track records to success in leadership roles. Usually, companies issue notices have no similar experience, resources, or any meaningful identification. Many companies do not actually commit to class securities actions, but only middlemen referring to clients or associates with law firms that are actually tilting in cases. Be wise in choosing advice. The Rosen Law firm represents investors around the world, concentrating its practice in the actions of securities class and shareholder derivative litigation. Rosen Law Firm has achieved the largest Securities Class Action Settlement against a Chinese Company at that time. Rosen Law Firm is ranked at No. 1 in ISS Securities Class action (WA 🙂 Services for the number of Securities Class Action Settlements in 2017. The company ranked in the top 4 each year since 2013 and recovered hundreds of dollars for investors. In 2019 only the company has gained more than $ 438 million for investors. In 2020, the founding partner Laurence Rosen was named the Law360 as Titan of Plaintiffs’ Bar. Many of the company’s lawyers are identified by lawdragon and super lawyers.

Case detail: According to Kha, the accused of the whole class has created a wrong impression that they have reliable information about cassava drug prospects and expected growths from a potential drug failure. However, in fact, the repeated statements of Cassava in Simufilam, the leading Cassava drug candidate, and confidence in rotating data that is not important in statistics to the potential of Simufilam; The boblen has no medication that prevents the development of Alzheimer’s disease, whether trying to treat only gentle and moderate cases. When real details enter the market, the man claims that investors suffer harm.

To participate in Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 Call Phillip Kim, Esq. Toll-free at 866-767-3653 or email [email protected] for information on the action in class.

No class has been confirmed. Until a class can be certified, you do not represent advice unless you hold one. You can choose and advice you want. You can also stay out of class and nothing can do this point. The ability of an investor in sharing any potential recovery in the future does not depend on serving as lead plaintiff.

Follow us for LinkedIn updates: https://www.linkedin.com/company/the-rosen-law-firm or Twitter: https://twitter.com/rosen_firm or facebook (nasdaq :): https : // /www.facebook.com/rosenlawfirm.

Advertising for Attorney. The first results cannot guarantee a similar result.

—————————-

To view the source version of this Press Release, please visit https://www.newsfilecorp.com/release/238388